We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

EUROIMMUN AG

  Silver Produces reagents for medical laboratory diagnostics, including test systems for the determination of various antibod... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Feb 2023 - 09 Feb 2023

Antiphospholipid Antibodies in Patients With Unexplained Articular Manifestations

By LabMedica International staff writers
Posted on 21 Dec 2022
Print article
Image: The SFRI IRE 96 is a simple and robust ELISA Absorbance Microplate Reader finds application in ELISA assays (Photo courtesy of HealthManagement.org)
Image: The SFRI IRE 96 is a simple and robust ELISA Absorbance Microplate Reader finds application in ELISA assays (Photo courtesy of HealthManagement.org)

Joint pain is the most common chronic pain making it one of the largest causes of disabilities in the world. Arthritis is a frequent condition that causes edema, redness, heat, loss of function and pain. It can affect one or more joints and there exist more than 100 different types.

Antiphospholipid antibodies (aPL) represent a complex and heterogeneous group of antibodies directed against anionic phospholipids or protein-phospholipid complexes. Persistent aPL have been associated with antiphospholipid syndrome (APS), which is defined by the presence of recurrent venous and/or arterial thrombosis and often pregnancy morbidity.

Immunologists at the Farhat Hached Hospital (Sousse, Tunisia) and their colleagues conducted a retrospective study including 313 patients suffering from arthritis or arthralgia without evident cause. Serum samples were collected from January 2017 to December 2019. Antinuclear antibodies (ANA), rheumatoid factors (RF) and anti-cyclic citrullinated peptides antibodies (CCP-Ab) were negative for all patients. Sera of 266 healthy blood donors (HBD) were included as normal controls.

The team detected aCL-IgG and IgM using an enzyme-linked immunosorbent assay (ELISA) kit and aCL-IgA were assessed by ELISA kit (Orgentec Diagnostika, Mainz, Germany). Highly purified cardiolipin was coated on microwells with β2GPI. Specific antibodies in the patient sample bound to antigen. microtiter plate reader and results were detected with an IRE 96microtiter plate reader (SFRI Medical Diagnostics, Saint Jean d'Illac, France). The scientists evaluated aβ2GPI-IgG and IgM by an ELISA kit (Orgentec Diagnostika) using a purified human β2GPI. aβ2GPI-IgA were assessed by ELISA kit. RF IgG, IgM and IgA were assessed using a three commercially ELISA kits, (Orgentec Diagnostika). CCP-Ab were measured by an available second-generation ELISA and ANA were detected by indirect immunofluorescence on HEp-2 cells (Euroimmun, Luebeck, Germany).

The investigators reported that out of the 313 patients, 250 were females and 63 were males. The mean age of patients was 49 ± 14 years (17–87 years). One hundred eleven patients have arthralgia and 202 have arthritis. The frequency of aCL and/or aβ2GPI (24.9%) was significantly higher in patients than in HBD (10.9%). The frequency of aβ2GPI was 23.6% in patients and 9.4% in the control group. aβ2GPI-IgA was significantly more frequent in patients than in the control group (20.4% versus 7.5%. aβ2GPI was most commonly observed than aCL in patients (23.6% versus 6.4%. IgA isotype of aβ2GPI was the most frequent in 20.4% of patients while IgG and IgM were detected in 5.4% and 2.9% respectively.

The authors concluded that they had demonstrated an elevated frequency of aβ2GPI-IgA in patients with unexplained arthralgia or arthritis. The possible pathogenic mechanism of aβ2GPI remained to be demonstrated and a prospective study is necessary to known if aβ2GPI-IgA will persist over time. The study was published on December 13, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Farhat Hached Hospital
Orgentec Diagnostika
SFRI Medical Diagnostics
Euroimmun

New
Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
3-Part Diff Hematology Analyzer
Aquarius 3
New
Gold Supplier
Specimen Collection & Transport
Specimen Collection & Transport Devices
New
Neonatal Biotinidase Ddeficiency Test
Neonatal Biotinidase

Print article
MEDLAB - INFORMA

Channels

Molecular Diagnostics

view channel
Image: A novel research study moves the needle on predicting sudden cardiac arrest (Photo courtesy of Pexels)

Newly Identified Protein Biomarkers in Blood Predict Sudden Cardiac Arrest Before it Strikes

Sudden cardiac arrest, or the sudden loss of heartbeat, is a life-threatening heart condition and often fatal. Despite providing an organized emergency medical response, less than 10% of individuals having... Read more

Microbiology

view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more

Technology

view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.